Tegaserod in the treatment of constipation-predominant irritable bowel syndrome. Do the risks outweigh the benefits?

Peter Wood

首页> 外文期刊>Naunyn-Schmiedeberg's Archives of Pharmacology >Tegaserod in the treatment of constipation-predominant irritable bowel syndrome. Do the risks outweigh the benefits?

【24h】

Tegaserod in the treatment of constipation-predominant irritable bowel syndrome. Do the risks outweigh the benefits?

机译：替加色罗治疗便秘为主的肠易激综合征。风险大于收益吗？

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Naunyn-Schmiedeberg's Archives of Pharmacology》 |2012年第1期|p.1-3|共3页
作者
Peter Wood;
展开▼
作者单位

Pathology Queensland, Princess Alexandra Hospital and University of Queensland, Australia, Ipswich Road, Woolloongabba, Queensland, Australia;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Tegaserod in the treatment of constipation-predominant irritable bowel syndrome. Do the risks outweigh the benefits? [J] . WoodP. Naunyn-Schmiedeberg's Archives of Pharmacology . 2012,第1期

机译：替加色罗治疗便秘为主的肠易激综合征。风险大于收益吗？
2. Tegaserod: a serotonin 5-HT4 receptor agonist for treatment of constipation-predominant irritable bowel syndrome. [J] . Cole P, Rabasseda X Drugs of today: Medicamentos de actualidad . 2004,第12期

机译：Tegaserod：5-羟色胺5-HT4受体激动剂，用于治疗以便秘为主的肠易激综合征。
3. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome. [J] . Harish K, Hazeena K, Thomas V, Journal of gastroenterology and hepatology . 2007,第8期

机译：替加色罗对便秘为主的肠易激综合症男性患者结肠转运时间的影响。
4. Different interventions for the treatment of irritable bowel syndrome-adjusted indirect comparison [C] . Qian Li, Wen-ting Liu, Jing-jun Xu, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：肠易激综合征调整后不同干预措施的间接比较
5. Social support, treatment adherence, and health related quality of life in people living with celiac disease and irritable bowel syndrome. [D] . Del-Colle, Melissa Marie. 2010

机译：患有腹腔疾病和肠易激综合症患者的社会支持，治疗依从性以及与健康相关的生活质量。
6. Treatment Algorithm for Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome Derived from a Canadian National Survey and Needs Assessment on Choices of Therapeutic Agents [O] . Yvonne Tse, David Armstrong, Christopher N. Andrews, 2017

机译：慢性特发性便秘和便秘型肠易激综合症的治疗算法来自加拿大国家调查和对治疗药物选择的需求评估
7. Tegaserod in the treatment of constipation-predominant irritable bowel syndrome. Do the risks outweigh the benefits? [O] . Peter Wood 2011

机译：Tegaserod治疗便秘 - 主要肠易激综合征。风险是否超过了好处？

Tegaserod in the treatment of constipation-predominant irritable bowel syndrome. Do the risks outweigh the benefits?

著录项

相似文献

相关主题

期刊订阅